| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4158 | 2014 |
| High Frequency of Mutations of the PIK3CA Gene in Human Cancers Y Samuels, Z Wang, A Bardelli, N Silliman, J Ptak, S Szabo, H Yan, ... Science 304 (5670), 554-554, 2004 | 4126 | 2004 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3032 | 2016 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2464 | 2010 |
| International network of cancer genome projects Data coordination centre Kasprzyk (Leader) Arek 1 Stein (Leader) Lincoln D ... Nature 464 (7291), 993-998, 2010 | 2143 | 2010 |
| Liquid biopsies: genotyping circulating tumor DNA. JLA Diaz, A Bardelli Journal of clinical oncology: official journal of the American Society of …, 2014 | 2142 | 2014 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2093 | 2008 |
| Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012 | 2038 | 2012 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 1890 | 2012 |
| Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013 | 1725 | 2013 |
| RAF/RAS oncogenes and mismatch-repair status H Rajagopalan, A Bardelli, C Lengauer, KW Kinzler, B Vogelstein, ... Nature 418 (6901), 934-934, 2002 | 1578 | 2002 |
| Integrating liquid biopsies into the management of cancer G Siravegna, S Marsoni, S Siena, A Bardelli Nature reviews Clinical oncology 14 (9), 531-548, 2017 | 1516 | 2017 |
| A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family C Ponzetto, A Bardelli, Z Zhen, F Maina, P dalla Zonca, S Giordano, ... Cell 77 (2), 261-271, 1994 | 1189 | 1994 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1156 | 2005 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 1038 | 2007 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1005 | 2015 |
| A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal CancerHER2 … A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corą, ... Cancer discovery 1 (6), 508-523, 2011 | 934 | 2011 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 899 | 2009 |
| A phosphatase associated with metastasis of colorectal cancer S Saha, A Bardelli, P Buckhaults, VE Velculescu, C Rago, BS Croix, ... Science 294 (5545), 1343-1346, 2001 | 870 | 2001 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 847 | 2010 |
